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Available online xxxxChemotherapy is a cornerstone of cancer therapy. Irrespective of the administered drug, it is crucial that adequate
drug amounts reach all cancer cells. To achieve this, drugs ﬁrst need to be absorbed, then enter the blood circu-
lation, diffuse into the tumor interstitial space and ﬁnally reach the tumor cells. Next to chemoresistance, one of
the most important factors for effective chemotherapy is adequate tumor drug uptake and penetration. Unfortu-
nately, most chemotherapeutic agents do not have favorable properties. These compounds are cleared rapidly,
distribute throughout all tissues in the body, with only low tumor drug uptake that is heterogeneously distrib-
uted within the tumor. Moreover, the typical microenvironment of solid cancers provides additional hurdles
for drug delivery, such as heterogeneous vascular density and perfusion, high interstitial ﬂuid pressure, and
abundant stroma. The hope was that nanotechnology will solve most, if not all, of these drug delivery barriers.
However, in spite of advances and decades of nanoparticle development, results are unsatisfactory. One promis-
ing recent development are nanoparticles which can be steered, and release content triggered by internal or ex-
ternal signals. Here we discuss these so-called smart drug delivery systems in cancer therapy with emphasis on
mild hyperthermia as a trigger signal for drug delivery.
© 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cancer is one of the leading causes of death and is expected to be-
come even more prominent with the worldwide continuously increas-
ing life span. While the improved understanding of the genetics and
themolecular basis of cancer, together with advances in early diagnosis
and therapy have resulted in improved clinical outcomes [1], cancer in-
cidence and relatedmortality are still rising. Chemotherapy is one of the
cornerstones in cancer treatment together with surgery and radiother-
apy. Chemotherapeutic agents can be used as a single treatment or as
a combination therapy with other drugs, or can be used in combination
with radiotherapy or surgery. One less common combination is chemo-
therapy together with hyperthermia, since hyperthermia is one of the
most widely studied chemo- and radiation sensitizer [2], and this com-
bination will be discussed in more detail later. Chemotherapeutic ap-
proaches have advanced enormously after the Second World War,
since the ﬁrst application of mustard gas derivatives for treatment of
lymphomas in the 1940s [3]. A vast number of new compounds were
identiﬁed and successfully used in patients. In spite of these advances
and the extensive research into new agents, chemotherapy suffers
from signiﬁcant limitations. Most of these compounds are highlyten Hagen).
. This is an open access article under
M. Amin, D. Haemmerich, et
g/10.1016/j.addr.2020.02.004cytotoxic to both cancer cells and normal tissue cells. The resultingmor-
bidity is that severe, such that the administered dose is typically limited
by toxicities (a.k.a. dose limiting toxicities). These toxicities are the re-
sult of (1) chemotherapeutics not being targeted to only reach cancer
cells, and (2) because agents are not selectively cytotoxic to cancer
cells. As a result of these dose limiting toxicities, relatively low drug
levels are obtained in tumors. Furthermore, a signiﬁcant number of che-
motherapeutic agents is poorly water soluble, complicating formulation
and administration of these compounds. Furthermore, the tumormicro-
environment with the disorganized vasculature and blood supply often
limits tumor drug uptake. The capacity of tumor cells to acquire resis-
tance to different chemotherapeutics, (multidrug resistance (MDR)), is
a factor that often leads to therapy failure [4,5]. Factors that contribute
towards MDR are drug efﬂux pumps via p-glycoprotein, pro-survival
signaling and interruption of apoptosis, and alterations in cell mem-
brane composition that reduce drug uptake [6–9]. Taken together,
there are a number of factors which are responsible for limiting chemo-
therapy efﬁcacy. There is substantial evidence that the usually low and
heterogeneous accumulation of drugs in tumors is a major reason for
treatment failure, i.e. the suboptimal outcome in patients is to a large
extend due to the inability to deliver adequate amounts of drug to all
cancer cells [10–14]. Because of the mentioned dose-limiting toxicity,
the administered dose cannot be further increased to achieve higher
tumor drug levels. Therefore, alternate strategies to improve tumor
drug delivery, while reducing systemic drug uptake are required.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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as important is reduction of co-morbidity. An effective method of
targeted tumor drug delivery that is already in clinical use is infusion
of the chemotherapeutic through the tumor feeding vessels (e.g.
chemoembolization), and takes advantage of the rapid extraction of
many chemotherapy agents, with the majority of drug extracted by tu-
mors during one pass [15]. Another strategy is isolated perfusion of the
tumor-bearing tissue or organ, where high drug concentration is main-
tained in part of the bodywith limited exposure of non-perfused tissues
[16–18]. In this review we will focus on strategies via nano-carrier
based drug delivery – amethod that also allows treatment of metastatic
disease.When ﬁrst proposed about 30 years ago, nanoparticles carrying
chemotherapeutics to the targeted tumors were considered to be the
solution for the hurdles identiﬁed above [19–21], improving both deliv-
ery to tumors while also diminishing non-target toxicities due to the
drug encapsulation. In addition, hydrophobic and poorly water soluble
compounds can be formulated and render applicable for systemic ad-
ministration. Finally, multiple active components could be incorporated
into one nanoparticle, which enables simultaneous delivery of these
multiple agents, to the same target tumor. Encapsulation of multiple
compounds can for example deliver drugs that interact synergistically,
or can deliver drugs together with imaging agents (e.g. MR contrast
agents) to enable visualization and monitoring of delivery.
While there have been some successful translation of
nanomedicines, these successes aremostly due to amore favorable tox-
icity proﬁle and therefore better tolerance of the treatment by patients.
However, rarely has improved clinical outcome been observed com-
pared to unencapsulated drug (i.e. standard chemotherapy). While the
clear advantages of nanomedicines in terms of reduced toxicity have
been recognized, it has become increasingly clear that the traditional
nanoparticle approaches have shown very limited success in enhancing
drug uptake by cancer cells. In this paper we will discuss an alternate
delivery strategy based on nano-sized smart drug delivery systems
(SDDS), which allow control of particle movement (i.e. steering), asFig. 1. Schematic representation of triggered drug release from smart drug delivery
systems (SDDS)/thermosenstive liposomes (TSLs) by externally applied mild
hyperthermia. SDDS/TSLs are systemically injected (syringe) and circulate throughout
the body. When passing the heated area (light grey zone over the tumor in the liver),
SDDS/TSLs are exposed to elevated temperatures of 39 to 42 °C and release content as a
result. This procedure results therefore in a loco-regional exposure of the tumor to free
chemotherapeutic.
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therapy, Adv. Drug Deliv. Rev., https://doi.org/10.1016/j.addr.2020.02.004well as control of release – i.e. allowing spatial and temporal control
(Fig. 1). Here, we will focus on SDDS with triggered release, i.e. where
either internal (e.g. pH) or external signals (e.g. temperature) serve as
release trigger. In addition, there have been considerable advances in
devices that allow spatial control of the trigger signal, such as focused
ultrasound devices or microwave devices for locally inducing hyper-
thermia that serves as trigger signal for SDDS. As we will discuss
below, the combination of triggered SDDS with appropriate devices
for controlling the external trigger signal can considerably enhance
tumor drug uptake compared to traditional nanomedicine, and may
achieve what prior nanoparticle approaches have failed by demonstrat-
ing improved therapeutic outcome compared to standard
chemotherapy.
2. Pharmacokinetics and tissue accumulation
2.1. Free chemotherapeutics
Chemotherapeutic agents can be administered by different routes,
such as oral administration, intravenous or intra-arterial injection/infu-
sion, local infusion or perfusion, direct intra-tumoral injection or by cre-
ating a (local) depot from which the drug is released over time. The
mode of administration impacts the life-time of the drug, the tumor ac-
cumulation, and also the severity and type of toxicity and morbidity
which accompanies the treatment. Lowmolecular weight chemothera-
peutics tend to have short plasmahalf-liveswhen administered intrave-
nously, and distribute throughout the body, thus having a large volume
of distribution (Fig. 2).While drug distribution to healthy tissues causes
undesired toxicity, it also limits tumor drug uptake, and together with
fast clearance and metabolization reduces the effective concentration
and exposure time of the drug in tumor tissue [22]. The interaction
with proteins in serum, such as albumin, can lead to a prolonged plasma
half-live and reduced dilution and degradation, which can have advan-
tages for drug delivery to solid tumors. However, these interactions tend
to be short-lived, and therefore do not prevent fast clearance and degra-
dation; these interactions also makes the drug pharmacokinetics of
more complex and patient dependent, since plasma composition is
highly variable [23]. Furthermore, even when a chemotherapeutic
agent reaches the tumor site, the pathophysiologic properties of the
tumor microenvironment (see section 3), provide additional barriers
that limit drug uptake at the tumor site. The heterogeneity of the
tumor microenvironment, not only between individual tumors but
also within the same tumor, provides additional challenges for an effec-
tive and homogeneous tumor drug distribution. As a result, cytotoxic
drug concentrations often do not reach all cancer cells, and gradients
of intratumoral drug concentrations exists [24]. Tumor regions with in-
adequate delivery contribute towards local tumor recurrence and may
even result in drug resistance [25–31]. While this is true for free drug,
it also applies to nanoparticles currently available for cancer treatment
[32,33]. Importantly, chemotherapeutic agents have the least favorable
therapeutic index of anticancer drugs currently being used,which limits
the dose or dose schedule that can be administered. Increasing the che-
motherapy dose to compensate for poor delivery is therefore typically
not an option, as this also increases exposure of systemic tissues and
therefore results in higher toxicity [34]. Therefore, either new and less
toxic drugs have to be developed, or existing drugs with a proven activ-
ity need to be reformulated (e.g. with nanoparticles) to address the bar-
riers limiting delivery, resulting in improved biodistribution and a
better therapeutic index.
2.2. Nanoparticle-formulated chemotherapy
Nanoparticles are intended to protect the encapsulated chemother-
apeutic agents fromdegradation, absorption,metabolismand excretion.
In addition, nanoparticles should also improve distribution, by limiting
the distribution volume to the blood volume, and thus improvingal., Hyperthermia and smart drug delivery systems for solid tumor
Fig. 2. Schematic representation of distribution, circulation time and tumor localization of chemotherapeutics in different administration settings. Free drug will generally distribute
throughout the body with a short (minutes) residence time in circulation and marginal amounts localize in the tumor. Classic nanoparticles (NP), may prolong circulation time but
most do not augment the amount of free drug in the tumor. Pegylation of NPs dramatically prolongs circulation time of the encapsulated drug. However, the amount of free drug in
the tumor is still low due to poor accumulation of the NPs and slow release of content (i.e. chemotherapeutic). Preheating of the tumor for 15 to 30 min increases vascular leakage and
promotes NP accumulation, although release of content is still slow. Exposing TSLs to mild hyperthermia triggers content release and when the heat is focused on the tumor elevated
drug levels result. Several factors are involved which determine high and prolonged presence of the release chemotherapeutic is the tumor. Together, selection of the optimal
chemotherapeutic, optimizing stability and circulation time of the nanoparticle, and optimizing response of the nanoparticle to a trigger (e.g. mild hyperthermia) need to be
considered to achieve increased and effective (i.e. free) drug concentrations in the tumor. Drug is presented in red while the carrier in yellow. The pharmacokinetics are represented
by red (drug) or yellow (carrier) lines in a log (concentration) versus time (linear) scale. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to
the web version of this article.)
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administration of poorly water soluble and hydrophobic drugs [35,36].
Ideally, nanoparticles change the pharmacokinetics and biodistribution
towards localization in the tumorwhile limiting uptake by other tissues.
In addition, it is important that the activity of the agent at the target site
is preserved [20,37,38]. This issue of target site activity is one of signiﬁ-
cance and will be discussed later in section 2.3. Initially, the hopes were
high for nanoparticles and they were suggested to be the “Magic Bullet”
previously postulated by Paul Ehrlich [39], which resulted in substantial
investment in nanomedicine development over the recent decades. A
large variety of organic and inorganic materials have been used in the
fabrication of a numerous nanoparticles such as liposomes, solid lipid
nanoparticles, micelles, polymeric nanoparticles, dendrimers, quantum
dots, protein based nanoparticles, carbon based nanoparticles, and
others. An155 assortment of nanoparticle design properties such as
size, charge, shape, type of surface modiﬁcation, and biocompatibility
have been investigated [40–43], and resulted in nanoparticles with
good stability and acceptable toxicity, some of which were successfully
applied in the clinic [44,45]. One signiﬁcant advancewas the realization
that rapid clearance of nanoparticles reduces their activity. In other
words, prolonged circulation timewas identiﬁed as an important factor.
One way to achieve such prolonged circulation was by coating ofPlease cite this article as: A.L.B. Seynhaeve, M. Amin, D. Haemmerich, et
therapy, Adv. Drug Deliv. Rev., https://doi.org/10.1016/j.addr.2020.02.004nanoparticles with polyethylene glycol (PEG), which rendered nano-
particles unrecognizable by the immune system (“stealth”), therefore
resulting in slower clearance and longer circulation time of up to several
days (Fig. 2) [19,46,47]. PEGylated liposomal doxorubicin (PLD)was the
ﬁrst clinically approved type of pegylated nanoparticle. In patients re-
ceiving PLD, clearance and volume of distribution were, respectively,
about 250-fold and 60-fold reduced [48]. Also the tumor accumulation
was drastically improved compared to free doxorubicin [49]. Since car-
diomyopathy is themain dose-limiting toxicity of free doxorubicin [50],
the reduced drug accumulation in the heart with the use of PLDs was a
major beneﬁt. The shift of toxicity to a less hazardous, and better con-
trolled palmar plantar syndromemakes prolonged drug dosing possible
and renders PLDs suitable for combination therapies. Similarly, protein-
bound paclitaxel (Abraxane®) or the polymeric micelle formulation of
paclitaxel (Genexol-PM™) enable higher administered doses compared
to the standard formulation of paclitaxel, Taxol™ ofwhich Cremophor is
used to solubilize paclitaxel, but causes hypersensitivity reactions [51].
A shorter infusion time and a reduced need for corticosteroid and/or an-
tihistaminic co-medication are other advantages of Abraxane® over
Taxol™ [36]. Liposomal vincristine sulfate (Marqibo®) has an increased
therapeutic index versus free vincristine. This enables higher doses to be
administered without increasing the neurotoxicity, even in extensivelyal., Hyperthermia and smart drug delivery systems for solid tumor
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(Onivyde®) improves pharmacokinetics and biodistribution of
irinotecan and protects it from early conversion to SN-38. Compared
to irinotecan, SN-38 is 100 to 1000 timesmore potent, but is susceptible
to rapid hydrolysis and inactivation by nonspeciﬁc carboxylesterases
[55–57]. Therefore, encapsulation provided beneﬁts by extending avail-
ability of the active compounds at the site of action while maintaining a
manageable safety proﬁle. While patients mainly beneﬁted from im-
proved safety, tolerability and increased therapeutic windows of
nanoformulated drugs [58], the limited impact on overall patient sur-
vival has become a major discussion point in the nanomedicine ﬁeld.
In summary, there have been several successful nanomedicines that
provide various beneﬁts in the clinic compared to the unencapsulated
compound, but beneﬁts are often related to an improved toxicity proﬁle
rather than a higher anti-tumor efﬁcacy. Clearer insights into the rela-
tionship between cancer biology and nanomedicine behavior is instru-
mental to make meaningful progress in nanomedicines [59].
2.3. Properties of nanoparticles for cancer therapy
The development of traditional nanoparticles has been primarily fo-
cused on creating a stable association of a drug with a nanoparticle in
order to protect the drug while in circulation, with the goals of (1) de-
creasing the volume of distribution and (2) prolonging circulation
time and/or retention at the diseased site. Ideally, this should result in
higher tumor accumulation and lower toxicity to healthy tissues. The
uniquely large surface-to-volume ratio of nanoparticles provides a
large functional surface to enhance the solubility or to carry a variety
of components. However, when initial nanoparticle formulations were
administered these were identiﬁed as foreign bodies and were cleared
rapidly by the reticuloendothelial system (RES), with only a small frac-
tion reaching the diseased site. Studies in patients demonstrated prefer-
ential uptake of liposomes by the RES [60]. By adjusting the lipid
composition, the circulation time of liposomes could be extended
from hours to days. For example when doxorubicin was encapsulated,
the volume of distribution was reduced from 365 L for doxorubicin to
5.9 L for liposomal doxorubicin (Doxil®) (both at a dose of 50 mg/
m2), but also resulted in a 4–16-fold enhanced accumulation in tumors
[46]. Higher intratumoral drug levels and longer retention of the drug
was observed both in preclinical models and in patients [61]. Improve-
ment in delivery of thedrug into the tumor site is believed to result from
the enhanced permeability and retention effect [62] which will be
discussed further below. Furthermore, this improved stability resulted
in reduced cardiac drug uptake and thus lower cardiotoxicity [63,64].
Severalmethods have been used to prevent opsonisation and clearance,
of which PEGylation is the best known and mostly widely used ap-
proach. Grafting nanoparticles with PEG (often referred to as stealth
nanoparticles) provides steric hindrance on the particle surface, thereby
minimizing aggregation, and reducing opsonization and macrophages
uptake. PEGylation thus reduces clearance rate and enhances circulation
time. Previously, Maruyama et al. observed that ganglioside GM1, com-
parable to PEGylation prolonged circulation of DPPC-based TSLs which
resulted in 2.5-fold increased local drugdelivery compared to liposomes
not containing GM1 and a better tumor response [65].
Important however is that for drugs to become active, dissociation of
the drug from the carrier has to occur. Papahadjopoulos and colleagues
observed that liposomal doxorubicin localizes in the extracellular ma-
trix of the tumor, and free doxorubicin enters the tumor cells upon deg-
radation of the liposomes [66], or as recently proposed by Barenholz by
means of remote release of doxorubicin due to reversed ammonium
gradient in the tumor [67].We observed in our studies however that re-
lease is a slowprocess taking place over several days [68].Moreover, we
demonstrated that tumor cells take up the intact liposomes, which are
then trapped inside tumor cells while retaining doxorubicin inside lyso-
somes (Fig. 3A) [68,69]. We hypothesize that this intracellular trapped
doxorubicin is not bioavailable since the drug either remainsPlease cite this article as: A.L.B. Seynhaeve, M. Amin, D. Haemmerich, et
therapy, Adv. Drug Deliv. Rev., https://doi.org/10.1016/j.addr.2020.02.004encapsulated or is retained in the lysosome/endosome, and therefore
not available to perform cytotoxic actions. Doxorubicin - like most
drugs - acts intracellularly. This means that the drug needs to pass the
cell membrane, and in the case of doxorubicin, also the nuclear mem-
brane. Measuring total levels of drug in tumors, as is common practice,
provides inadequate information and knowledge of drug levels at the
intracellular biological target is necessary; for doxorubicin, this drug tar-
get is the nucleus [68,70].
It has become increasingly clear that improved intratumoral delivery
by nanoparticles does not necessarily imply improved delivery or inter-
action of the chemotherapeutic payload with the subcellular target. A
good example is long circulating liposomal cisplatin where despite suc-
cessful tumoral delivery, no therapeutic beneﬁt over treatment with
free cisplatin was observed because of the lack of release of cisplatin
from liposomes [71]. Therefore, in addition enhanced tumor delivery,
adequate bioavailability of the active compound is necessary, i.e. the
chemotherapeutic agent has to dissociate from the nanoparticle in a
timely fashion to assure an effective cytotoxic concentration at the bio-
logical target. Based on the discussion above, and to complicate the pic-
ture further, also vascular and tumoral barriers need to be taken into
account since they greatly impact the accessibility of tumor cells to
the nanoparticles, as will be discussed below. Clearer insights into the
relationship between cancer biology and nanomedicine behavior is in-
strumental to make meaningful progress in nanomedicines [59].
Taking the above potential and limitations of drug carriers into ac-
count it becomes clear that the ideal properties of nanoparticles, i.e.
great stability in circulation and rapid dissociation at the side of action,
oppose each other and are difﬁcult to realize in traditional nanoparti-
cles. This realization initiated the development of advanced nanoparti-
cles which we coined smart drug delivery systems (SDDS).
3. Tumor microenvironment
3.1. Introduction
For a drug to be effective it is important to reach the target, which is
typically located within a speciﬁc compartment of the cancer cells. Irre-
spective of size, tumors do not solely exist of cancer cells but often also
contain a large fraction of stromal cells (e.g. endothelial cells, pericytes,
ﬁbroblasts and immune inﬁltrating cells) and matrix components (e.g.
basalmembrane and extracellularmatrix). This stroma is highly impor-
tant in tumor development as it creates a connective and supporting
framework and forms a reservoir of factors promoting tumor mainte-
nance and growth. Stromal cells may support tumor growth, facilitate
and promote the tumor vascular bed, and may protect the tumor from
attacks by the immune system. Importantly, this tumor microenviron-
ment plays also a pivotal role in chemotherapy delivery and therefore
development of delivery systemsmust consider the tumor composition
of the microenvironment [72]. A solid tumor has several key properties
that are not found in normal tissues, including (1) an abnormal vascular
network (i.e. heterogeneous and chaotic vessel growth, non-functional
vessels and shunting of blood [73]), (2) accumulated solid stress be-
cause of the rapid tumor growth, and (3) an elevated interstitial ﬂuid
pressure (IFP) due to increased permeability of the tumor-associated
vasculature in combination with the lack of a functional lymphatic
drainage. IFP in turn causes blood ﬂow stasis and reversed blood ﬂow,
which hinder drug uptake by tumor regions with high IFP. Chauhan
et al. argue that in pancreatic cancer, IFP is driven by blood pressure,
while solid stress causes vessel compression, and that relaxation of
this stress improves therapeutic outcome [74,75]. Another barrier for ef-
fective drug uptake is the overproduction of extracellular matrix pro-
teins, contributing to solid stress and compressed tumor vessels [76].
These barriers together with the perfusion defects result in hypoxia
and acidosis, with necrotic and non-perfused tumor regions. Cancer
cells are often more resistant to chemotherapeutic drugs in these
regions.al., Hyperthermia and smart drug delivery systems for solid tumor
Fig. 3. Intravital images of nanoparticle fate in tumors. (A) Lysosomal sequestering of nanoparticles. Live cell imaging of human melanoma cells exposed for 24 h to Doxil with an
incorporated DiD label or doxorubicin. Lysosomes are visualized using a live cell lysosomal marker-green. When administered as a nanoparticle doxorubicin and the carrier sequesters
in lysosomes, whereas free administered doxorubicin is located in the nucleus. (B) Entrapment of nanoparticles in the vessels. Intravital imaging in a murine tumor 24 h and 36 h after
administration of nanoparticles. Seen here is the presence of a placebo nanoparticle visualized with rhodamine or Doxil with an incorporated DiO label in the vasculature (white
arrows) and no to minimal extravasation into the tumor tissue occured. (C) Extravasation of the same nanoparticle formulations combined with the vaso-active compound tumor
necrosis factor alpha (TNF) 24 h and 36 h after systemic administration. Nanoparticles are found in the tumor interstitium with few nanoparticles remaining in the vasculature (white
arrows). (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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Blood vessels consist of an endothelial cell lining surrounded by
perivascular cells (i.e. smooth muscle cells or pericytes), and a basal
membrane enveloping both cell layers. The endothelial cells form the
inner lining of blood vessels, providing a dynamic barrier between the
underlying tissue and the blood. Perivascular cells are wrapped around
endothelial cells, provide structural support to the vessel tube and reg-
ulate vascular tone. However, the complex molecular association with
endothelial cells suggests that perivascular cells serve more than just
support [77,78]. Angiogenesis, the formation of new blood vessels
from existing blood vessels, is tightly regulated under normal condi-
tions and occurs in adults only under special circumstances such as
wound healing and placental growth. However, under pathological con-
ditions like tumor growth, the balance between pro and anti-angiogenic
factors is in favor of angiogenesis, resulting in uninhibited, and impor-
tantly, uncontrolled angiogenesis. Because of this lack of control of
tumor-associated vessels, many features of tumor vessels differ from
normal vessels and display a lack of hierarchical branching organization
in which the recognizable features of arterioles, capillaries and venules
is lost [73]. Vessels are tortuous and unevenly dilated, with shunts
being present between feeding vessels. As a result, tumor blood ﬂow
is chaotic, can be stationary, and can even change direction. Because of
the relatively fast growth and abundance of pro-angiogenic factors
such as VEGF, tumor vessels do not completely mature. Endothelial
cells and pericytes are not nicely aligned [73,79] and gaps can be
found in the vascular lining [80] making them leaky for ﬂuid, molecules
and nanoparticles. This vascular leakiness contributes, in combination
with an ineffective lymphatic system, to an increased interstitial ﬂuid
pressure [81].
3.3. Tumor-associated stroma
Also stromal cells differ from healthy tissue in a way that limits drug
delivery. Tumors tend to have an abundance of ﬁbroblasts and inﬁltrat-
ing immune cells.While these normally provide regulatory, suppressive
and constructive support, in tumors these cells contribute towards
growth, as tumor cells may manipulate tumor-associated ﬁbroblasts
and immune cells towards a pro-tumoral status. These cells also serve
vital roles in wound healing and it was Haddow who in 1972 asked
the question, whether tumor growth can be considered a process of
overhealing [82]. This question was later reexamined by Dvorak [83],
seeing tumor stoma strongly resembling stroma of granulated tissue,
and suggesting that tumors are equivalent to wounds going through a
permanent healing response – or “a wound that never heals”. During
wound healing, ﬁbroblasts synthesize extracellular matrix, maintain
the microenvironment, and sustain cell growth. In later stages ﬁbro-
blasts are responsible for remodeling the temporary extracellular ma-
trix into a permanent composition which results in tissue contraction.
Also in cancerous tissue these cells contribute to production of extracel-
lular matrix components and remodeling enzymes. However, while in
normal healing conditions, unwanted ﬁbroblasts are removed via apo-
ptosis, this safety feature is lost in the chronic proliferative tumor envi-
ronment.Multiple layers of ﬁbroblasts at high density are often found at
the invasive front of a tumor [84], providing support and integrity of the
tumormass. Theseﬁbroblasts, togetherwith overproducedmatrix com-
ponents, can form a densewall between tumor cells and feeding vessels.
This condition is referred to as desmoplasia and is for instance present in
pancreatic cancer, where it is recognized as a major factor contributing
to the poor response of pancreatic cancer to chemotherapy. Various ap-
proaches to reduce this barrier or enhance its permeability have been
investigated to improve drug delivery [85,86]. In section 4 we will dis-
cuss how to improve nanoparticle accumulation in solid tumors using
hyperthermia or vasoactive agents to manipulate the tumor microenvi-
ronment. Immune cells serve a pro-inﬂammatory role during the initial
stages of wound healing and later have an anti-inﬂammatory rolePlease cite this article as: A.L.B. Seynhaeve, M. Amin, D. Haemmerich, et
therapy, Adv. Drug Deliv. Rev., https://doi.org/10.1016/j.addr.2020.02.004during the constructive processes of wound healing and tissue repair.
As “a wound that never heals” tumor-associated immune cells are
often polarized towards the anti-inﬂammatory pathway releasing sev-
eral pro-tumorigenic cyto- and chemokines [87], as well as towards a
tumor protective and tumor promoting direction. Immune cells present
in the tumor can have a great impact on treatment outcome. Recent re-
sults clearly show that activation or modulation/manipulation of the
immune system holds great promise and we think also in this ﬁeld
nanotechnology canplay a signiﬁcant and important role,which is how-
ever outside the scope of this review.
3.4. Enhanced permeability and retention (EPR)
Why would a nanoparticle, which is about a thousand-fold larger
than the free drug, perform better in the treatment of solid cancer? As
mentioned above, when accumulation of drugs in tumors was studied,
circulation time directly correlated with intratumoral drug levels (i.e.
the longer a drug circulated, the more was found inside a solid cancer).
Notably, this longer circulation time is oneof themain features provided
by the nanoparticle. Matsumura et al. observed in 1986 that nanoparti-
cles had the tendency to accumulate in murine solid tumors [62]. This
phenomenon was termed the enhanced permeability and retention
(EPR) effect and was attributed to the leaky tumor-associated vascula-
ture and impaired lymphatic system, as recently reviewed byGolombek
et al. [88]. Once a blood-born nanoparticle reaches the tumor site, as a
result of the disorganized and permeable vasculature, the nanoparticle
leaks out into the tumor interstitium and because of the lack of drainage
has the tendency to remain there. This effect is mainly observed in ex-
perimental murine tumors and is less noticeable in human tumors. An
effective tumor response solely based on the EPR effect requires a uni-
form permeability and retention throughout the tumor and this is usu-
ally not the case. Tumor heterogeneity is a major problem for effective
drug delivery and is not only observed between tumors [89] but more
importantly also spatially within a tumor [75,90]. Whether tumor
areas are hypo- or hyperperfused, have mature vessels or leaky imma-
ture vessels, have functional or static blood ﬂow, all these heterogene-
ities translate into the heterogeneity of the EPR effect. Matsumoto
et al. argue that permeability of the vasculature also results from a dy-
namic process with bursts of extravasation occurring rather randomly
[91]. The retention is attributed to the lack of drainage via a lymphatic
system and due to a dense extracellular matrix compartment, and
these mechanisms prevent nanoparticle penetration. Because a human
cancer grows slower compared to experimental transplanted murine
tumors, this heterogeneity in human cancers is even more prominent
while vessels appear to be less leaky compared to animal models.
Recently, Sindhwani et al. stated that nanoparticle extravasation does
not proceed via endothelial gaps, but through a dynamic and active
process possibly including transcellular channels [92]. If true, this may
suggest alternate approaches to enhance nanoparticle based tumor
uptake. The therapeutic efﬁcacy of Doxil®, the ﬁrst nanodrug approved
for human trials, is superior to free doxorubicin in AIDS-related Kaposi
sarcoma and advanced ovarian cancer [93,94]. For other cancer types
however, the efﬁcacy compared to free drug is rather modest [95–97].
Strikingly, administration of Doxil® gives an area under the curve
(AUC) 600-fold higher compared to free drug [46,98], and this was
thought to improve clinical outcome. The general conviction was that
with a higher AUC in blood, more drug will get to the tumor because
of the EPR, and thus a better tumor response is achieved. However, it
turned out that the AUC in blood of a drug-loaded nanoparticle does
not predict outcome. This is an important observation that relates to
the bioavailability of nanomedicines, and will be discussed in more de-
tail below. In our studies withmurine tumors where we focused specif-
ically on the location of both the carriers and the chemotherapeutic
drug, we observed that nanoparticles remained predominantly in the
vasculature and extravasation into the tumor interstitiumwas minimal
during the ﬁrst hours (Fig. 3B) [69]. In addition to the barriers limitingal., Hyperthermia and smart drug delivery systems for solid tumor
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tivity directly by absorbing a signiﬁcant fraction of a drug in the tumor.
By doing so, these cells sequester drug and thus lower the drug amount
available for cancer cells, while also restricting drug penetration further
into the tumor. This phenomenon is important to consider as resistance
to chemotherapeutics is especially noticeable in the lower concentra-
tion range. Even drug delivery strategies using active targeting, in
which nanoparticles are grafted with a speciﬁc ligand, still rely on pas-
sive extravasation and homogenous distribution throughout the
tumor to effectively target all tumor cells, and therefore active targeting
cannot overcome any inherent limitations of the EPR effect. Currently,
there is a lot of controversy in regards to relevance of the EPR effect of
Danhier [99] versus Man [100]. Therefore smart drug delivery systems
that do not rely on the EPR effect are becoming of considerable interest.
A recent review paper by Wilhelm et al. suggested that the delivery
efﬁciency of nanoparticles has remained low and did not improve
throughout the last decade of intense research with an average tumor
nanoparticle uptake of 0.7% injected dose per tumor in 2015, the same
as it was in 2005 [101]. These results further suggest that the inherent
limitation of nanoparticles based on the EPR effect are difﬁcult to over-
come by novel nanoparticle designs, and that an alternate strategy that
does not depend on the EPR effect may be necessary to improve on this
modest tumor uptake.
In addition to any limitations of the EPR effect, inadequate release or
dissociation of the drug from the nanoparticle at the target site is a
major limitation of many nanoparticles. Even if nanoparticles extrava-
sate from the blood circulation into the tumor microenvironment, mi-
grate across stromal compartments, and accumulate in high amounts
in the tumor for extended duration, the encapsulated drug still needs
to be released to become biologically active. Release from the carrier
can be extra- or intracellularly, and for many chemotherapeutics, as is
for instance the case for intercalating agents, the drug needs not only
to enter the cell but also the nucleus.While commonly ignored, efﬁcient
and timely release of content by the nanoparticles is not trivial to
achieve, and is a major focus in drug delivery research. For example, re-
quirements for a liposomal carrier to achieve long circulation time and
high stability are PEG coating, and either a robust bilayer of rigid phos-
pholipids or cholesterol to reinforce the bilayer. In general, the required
rigidity of nanoparticles for stable drug encapsulation becomes a limita-
tion after nanoparticles enter the tumor interstitium, as most of the
drug remains encapsulated and release is limited and too slow [68,69].
The resulting low bioavailable drug level is in part accountable for the
low therapeutic efﬁciency compared to free drug administration and
the need for repeated administration. Possible strategies to address
this particular issue are discussed in the next section.
4. Improving drug and nanoparticle accumulation
4.1. Tumoral delivery of nanoparticles
As described above, intratumoral accumulation of nanoparticles is
thought to result from the EPR effect. As also noted, EPR is a stochastic
process and is now considered to be quite inefﬁcient. One way to im-
prove nanoparticle accumulation in tumors is by active targeting via li-
gands attached to the outer surface of the nanoparticles. It was assumed
that decoration of nanoparticles with targeting ligands towards recep-
tors that are highly overexpressed on tumor cells or tumor vasculature
will improve intratumoral accumulation and increase cellular internali-
zation [102]. However, there is now consensus that active targeting
does not necessarily improve tumor accumulation of nanoparticles
[103], and a recent review paper found on average an onlymodestly im-
proved tumor drug uptake of 0.9% injected dose/tumor for actively
targeted compared to 0.6% for passively targeted nanoparticles [101].
One disadvantage is that the addition of any antigen or recognizable
moiety at the nanoparticle surface causes augmented clearance. This
shortens circulation time [104,105], and since circulation time dictatesPlease cite this article as: A.L.B. Seynhaeve, M. Amin, D. Haemmerich, et
therapy, Adv. Drug Deliv. Rev., https://doi.org/10.1016/j.addr.2020.02.004tumor accumulation, tumor uptake is reduced [103,106,107]. We dem-
onstrated that ligand modiﬁcation of nanoparticles not only reduces
penetration depth, but also that endocytosed doxorubicin-loaded lipo-
somes remain inside lysosomes for extended duration [108]. Based on
these observations, additional research has been conducted in an at-
tempt to modify or exploit the tumor pathophysiology to improve or
bypass EPR-driven accumulation.
Accumulation of a nanoparticles or drugs in tumors can be enhanced
by improving perfusion. Strikingly, antiangiogenic therapy with VEGF
neutralizing antibodies results in better perfusion of the tumor
[109–111], and as most drugs are blood born, the augmented bulk
ﬂuid through a tumor results likewise in a higher drug delivery to the
tumor. This however only helps the delivery of small (i.e. free drug)
compounds as inhibiting VEGF results in vascular normalization and
with that closing of the gaps between endothelial cells, thus eliminating
the EPR effect [111,112]. We have demonstrated that the opposite ap-
proach is more effective, and showed that enhancing vascular perme-
ability with Tumor Necrosis Factor alpha (TNF-a) – an effect we
termed “vascular abnormalization” [113] - improved intratumor accu-
mulation of free drug during isolated perfusion [114,115], and also im-
proved the accumulation of nanoparticles when administered
systemically [69,116]. This approach is based in part on the realization
that tumor vessels less ﬁrmly attached to the matrix, which renders
the endothelial cells more sensitive to certain cytokines, vasoactive
agents such as TNF-a, and histamines [117–119].
4.2. Strategies to enhance tumor uptake
4.2.1. Modiﬁcation of vascular function or vascular integrity
As noted, tumors have both features that can impair drug uptake as
well features that can enhance uptake. Importantly, abnormalities in
tumor vasculature, stroma and other microenvironmental conditions
can be targeted and manipulated to speciﬁcally augment tumor drug
uptake and thus outcome. Several strategies have been suggested in
which the tumor-associated vasculature was exploited to improve
drug delivery. Anti-angiogenic therapy not only inhibits new vessel
growth, but also changes the tumor-associated vasculature more re-
sembling normal vascular [110,111,120]. This normalization is associ-
ated with a reduction in interstitial ﬂuid pressure and increased
oxygenation, which both result in a better penetration of chemotherapy
agents, as well as higher cytotoxicity of chemo- and radiotherapy
[110,120]. This normalizing strategy is applicable to nanoparticles and
agents less than 40 nm in size (e.g. free chemotherapeutic agents, ormi-
celles), since larger nanoparticles are dependent on the abnormal tumor
vasculature and associated EPR effect [111,121]. To enhance the accu-
mulation of such larger nanoparticles requires alternate strategies,
such as enhancing the permeability of the tumor-associated vascula-
ture. We and others have demonstrated that co-administering of vaso-
active compounds or external hyperthermia further enhances the
already increased vascular permeability to obtain a better andmore ho-
mogeneous nanoparticle distribution [69,122]. This strategy is particu-
larly relevant for augmenting extravasation of larger particles, like
liposomes. We demonstrated that a low, non-toxic dose of TNF-α spe-
ciﬁcally augments the intratumoral drug accumulation of doxorubicin-
containing liposomes, and by doing so, renders a prior ineffective dose
into an effective one. Speciﬁcally, a dose regimen of Doxil® that initially
had 100% non-responders, produced a partial or complete response in
75% of the subjects when combined with TNF-α [69,123,124]. We also
found that the addition of TNF-α augmented intratumoral drug concen-
trations more than 6-fold by increasing permeability of the endothelial
lining (Fig. 3C) [69,116]. Others demonstrated that nanoparticles can be
used to deliver plasmids to modify pro- to anti-tumorigenic properties
of cancer-inﬁltrating ﬁbroblasts, as demonstrated by Miao et al. [125].
Furthermore, reducing the extracellularmatrix decreases the interstitial
pressure, resulting in a better tumor perfusion and improved drug up-
take [126]. As an example, Losartan, an angiotensin II receptoral., Hyperthermia and smart drug delivery systems for solid tumor
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collagen and thereby enhancing tumor perfusion [72], but also through
inhibiting cancer-associated ﬁbroblasts that are responsible for collagen
production [127]. In addition to sequestration of drugs, ﬁbroblast can
also physically block drug penetration. This is the case for example in
pancreatic cancer, where ﬁbroblasts together with the tumor matrix
form a wall between tumor vessels and tumor cells. Olive et al. show
that depletion of this stromal barrier in pancreatic cancer greatly im-
proves drug delivery and improves survival in a mouse model [128].
Particularly relevant for this review is that mild hyperthermia is able
to manipulate the tumor-associated vasculature to enhance uptake
[32], and this topic will be discussed in the next section.
4.2.2. Mild hyperthermia as facilitator of nanoparticle delivery
Localized hyperthermia therapy, which consists of artiﬁcially raising
of the temperature in a part of the body, is used clinically in various
forms (Fig. 1). At higher temperatures, above 50 °C [129], it is used to di-
rectly kill tumor cells, and is termed “thermal ablation” [130,131]. At
lower temperatures of around 42 °C, it is referred to as mild hyperther-
mia, with a number of clinical applications and physiological responses
as documented by Issels et al. [2]. In their review, the ‘hallmarks of hy-
perthermia’ are listed as: (1) blocking cell survival, (2) inducing cellular
stress response, (3) modulating immune response, (4) evading DNA re-
pair, (5) changing tumormicroenvironment, and (6) sensitization to ra-
diation and chemotherapy. To this we can add mild hyperthermia as a
trigger for controlled drug release from thermosensitive nanoparticles
as described in detail in section 6. Raising the whole body temperature
as happens during fever, or locally raising the temperature through an
external energy source, induces a number responses, some likely still
unknown. When hyperthermia is applied to tumors, either direct cell
kill may be achieved, or the cells become sensitized towards radiother-
apy and chemotherapy, possibly in part due to interference with DNA
repair mechanisms by degradation of BRCA2 [132,133]. A combination
of standard chemotherapy with regional hyperthermia improved both
short-time but and long-time (10 years) survival in sarcoma patients
[134,135]. As Killock states, regional hyperthermia affects a range of cel-
lular targets and processes, including DNA repair, the tumor microenvi-
ronment, and anticancer immunity, whichmight explain the consistent
prolonged beneﬁt [136]. Wewill later also discuss the effect that hyper-
thermia has on the tumor microenvironment with respect to
nanoparticle-mediated drug delivery.
As alreadymentioned hyperthermia can be used to augment the EPR
effect. For example, Huang et al. observed that intratumoral drug levels
where 1.5-fold higher when tumors were exposed for 30 min to 42 °C
after injection of liposomal doxorubicin compared to 37 °C (Fig. 2). In
comparison to free drug, drug levels after liposomal doxorubicin admin-
istration was 15-fold higher, suggesting that hyperthermia is most ben-
eﬁcial when combined with a long circulating drug or formulation
[137]. Nevertheless, hyperthermia also improves accumulation of drug
and outcome when combined with free drug through modulation of
intratumoral ﬂuid dynamics such as increased blood ﬂow and vascular
permeability [138,139]. Kong et al. show that exposing tumors in vivo
to 42 °C for 1 h increases the pore cutoff size of tumor vessels to
N400 nm allowing all tested liposomes (100 to 400 nm) to extravasate,
whereas at normothermia cutoff sizewas between 7 and 100 nmand li-
posomal preparations did not extravasate [140,141]. We previously ob-
served that large gaps between endothelial cells occur after mild
hyperthermia in all tumor types tested and that this process is revers-
ible with tumor vessels returning to the initial conditionwithin approx-
imately 8 h [32]. This hyperthermia response is absent in normal
vessels. While hyperthermia has shown beneﬁts for nanoparticle deliv-
ery, it still relies nanoparticle extravasation, and only a small fraction
(~1 to 5% of the injected dose per gram tumor tissue) are taken up by tu-
mors [142,143]. In addition, the limited bioavailability of the still encap-
sulated drug is not addressed by this approach, and section 6 focuses
speciﬁcally on this topic.Please cite this article as: A.L.B. Seynhaeve, M. Amin, D. Haemmerich, et
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A wide variety in systems exists for the application of local hyper-
thermia, employing various energy sources, and for different treatment
volumes. The differences are in the method of energy transfer to tissue,
the size of the volume that can be heated, externally or internally ap-
plied energy and ﬁnally the ability to control the temperature within
the desired range of a fewdegrees Celsius. In general, hyperthermia sys-
tems providing better spatial control of heating involve more complex
technology for heating and temperature monitoring, and are more
costly. Other relevant factors related to the integration into the clinical
workﬂow are discussed elsewhere [144–146].
5.1. Devices for externally applied hyperthermia
Most clinical hyperthermia systems are based on electromagnetic
(EM) energy to heat tumor and the surrounding tissue [147]. The inter-
action of EM ﬁelds with tissue results in drift of ions and oscillation of
electric dipoles (i.e. water). The resulting friction produces tissue
heating. The speciﬁc heating mechanism depends on the frequency
and direction of the EM ﬁeld aswell as on the electrical properties of tis-
sue. A beneﬁt of EM based hyperthermia systems is their ability to heat
large (up to 10–15 cm, Fig. 4) tissue volumes independent on location
within the body. At frequencies of N50 MHz transfer of the EM energy
is radiative whereby increasing the frequency results in a smaller
heating focus and reduced penetration depth. Small and large sized su-
perﬁcially located tumors with depths up to 4 cm from the skin are in
general heated at the frequencies approved for medical use, which are
of 434 MHz in Europe and 915 MHz in the USA. Optimal spatial control
is obtained by using multiple (2–24) applicators, while controlling the
energy output of each individual applicator. Annular phased array appli-
cator systems consisting of 4–12 applicators with constructive interfer-
ence are used to heat advanced, deep seated tumors in the abdomen or
pelvis region. Hyperthermia treatment planning is often employed to
calculate the optimal phase and amplitude setting to maximize tumor
heating. In general, radiative hyperthermia systems are considered the
most advanced technology as they allow for dynamic adaptation of
the spatial energy distribution. Alternatively, radiofrequency capacitive
hyperthermia systems are available that can heat both superﬁcial and
deep located tumors. Capacitive hyperthermia systemsuse less complex
technology, but lack spatial control of the energy distribution. A disad-
vantage of capacitive systems is that only the total amount of applied
energy can be controlled, and during deep hyperthermia preferential
heating of the fatty tissue occur. The latter limits the use of this technol-
ogy for heating of deep seated tumors in the pelvic region to patients
with a fat layer less than 2 cm thickness [148].
High intensity focused ultrasound (HIFU) is increasingly clinically
used for high-temperature application (i.e. thermal ablation), but less
widely employed for mild hyperthermia therapies [149]. The pressure
wave applied during HIFU causes small tissue vibrations, and the resul-
tant friction produces heat. Clear advantages of HIFU over EM heating
are the deep penetration and the ability of very focused heating [130].
One disadvantage of HIFU is the high reﬂection at air (99%) and bone
(60%) interface as well as the high absorption in bone. Therefore, not
all locations are accessible by HIFU since it requires that no air or bone
(e.g. lung, rib cage) are present between the ultrasound transducer
and the target tissue. With current HIFU systems, small tumors with a
diameter up to 3 cm at deep locations up to 15 cm can be heated. For
larger tumorswith a size up to 15 cm, planarmultisource ultrasound ap-
plicators maybe be used. Alternatively, by applying HIFU with a blurred
focus in combination with rapid electronic scanning of the focus it has
been shown that superﬁcially located tumors with a diameter up to 5
to 6 cmcan be heated (Fig. 4). Enhancing the ability to heat large tumors
at depth is still subject of ongoing research [150].
Several studies have investigated the combination of HIFU hyper-
thermia with heat-triggered SDDS [150–154], and results of a Phase Ial., Hyperthermia and smart drug delivery systems for solid tumor
Fig. 4.Heating properties of ultrasound (US) and radiative electromagnetic (EM) heating devices. Capacity to heat efﬁciently tumors of certain size (x-axis) and at certain tumor depth (y-
axis) is depicted. EM allows heating of large tumors at most, if not all, body sites, while US can be used for smaller, or more superﬁcial tumors.
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number NCT02181075) [155]. The ability of accurate spatial targeting
combined with guidance of hyperthermia by MR thermometry allows
for accurate control of tumor temperature within the ideal temperature
range, and very promising tumor responses have been achieved with
complete regression reported by two recent animal studies [153,154].
Another subject of research has been the co-encapsulation of MR con-
trast agents together with a drug in heat-triggered SDDS
[138,150,156], allowing MR imaging of contrast agent release to serve
as surrogate for drug release [157–160].
5.2. Devices for internally applied hyperthermia
In devices for internally applied hyperthermia, an applicator is
placed in the tumors (i.e. interstitially), usually guided bymedical imag-
ing such as ultrasound, computed tomography (CT), or MR imaging. As
the device is placed directly in the tumor, heat is localized within the
tumor with limited heating of distant tissues [161]. Various devices for
internal hyperthermia have been described [162], and particularly
those based onultrasound andmicrowaveheatinghave achieved prom-
ising results. Typically, such devices require placement of a probe or
catheter (usually ~1–3 mm in diameter) in or near the targeted tissue
region (e.g. tumor). Internal ultrasound based devicesmay employmul-
tiple transducers and are able to provide directional heating [163–166],
and such devices have been clinically investigated for treatment of pros-
tate cancer and benign prostate hyperplasia by hyperthermia [167,168].
A recent microwave based device provides directional heating as well
[169], and both ultrasound andmicrowave based internal hyperthermia
devices have been combined with MR thermometry to provide real-
time feedback on tissue temperature [164,166,169]; this aspect is im-
portant when combined with heat-triggered SDDS, since target tissue
temperature needs to be controlled within a relatively narrow temper-
ature range (ideally ~40–43 °C).
To limit damage to tissue during placement of the hyperthermia de-
vice, the applicator is ideally small enough in diameter to allow a mini-
mally invasive approach. Magnetic nanoparticles (MNPs), like iron
oxide particles, have been investigated for hyperthermia because of sev-
eral speciﬁc features [170]. The small size allows them to reach the
tumor cell, they can be tagged with tumor antibodies, the magnetic
properties can be used to target theMNPs to the tumor, and in combina-
tion with a time-varying magnetic ﬁeld the MNPs can be used to heat
the tissue. Depending upon the goal, MNPs have been administered by
various routes. Direct intratumoral injection of the MNPs is reported
to bemost effective for bulk heating of the tumor in animals, but is prob-
lematic in larger tumors due to heterogenous MNP distribution. MNPsPlease cite this article as: A.L.B. Seynhaeve, M. Amin, D. Haemmerich, et
therapy, Adv. Drug Deliv. Rev., https://doi.org/10.1016/j.addr.2020.02.004can improve drug uptake by: 1) facilitating extravasation of the chemo-
therapeutic drug when applied in a systemic way, i.e. heat from the
MNPs increases vascular permeability, or as packaged in
thermosensitive liposomes (TSL), i.e. heat from theMNPs trigger the re-
lease of content fromTSLs. And 2) heat from theMNPs present in the tu-
mors may cause thermal sensitization of the tumor cells to the
chemotherapy. When MNPs are applied intravenously the tumor con-
centration of MNPs achieved is usually insufﬁcient to induce adequate
tumor heating. An alternate strategy that has been examined is the en-
capsulation of MNPs in TSLs to enable triggering of drug release from
TSL by magnetic ﬁelds [171].
5.3. Thermometry
Accurate thermometry during hyperthermia requires either the in-
sertion of interstitial catheter for invasive temperature measurements
using multi-sensor probes, or some type of image-based thermometry.
When a hyperthermia system is integrated with magnetic resonance
imaging (MRI), a 3-dimensional temperature distribution can be mea-
sured using non-invasively based on MR-thermometry [172,173]. Typi-
cally, MR thermometry is based on the temperature dependence of the
proton resonance frequency [174]. A disadvantages of MR thermometry
is the susceptibility tomotion artifacts, which is problematic in some or-
gans where movement is prevalent such as the liver, or pelvic and ab-
dominal regions where movement of intestines is an issue. MR-
thermometry works well in locations without movement, such as in
soft tissue sarcomas in the extremities, temperature measurement in
the pelvic and abdomen region aremore affected bymovement of intes-
tines and the patient. In addition, research is ongoing to investigate the
potential of the MRI relaxation parameters R1 and R2 as a parameter to
quantify cargo release of TSLs [159,160].
5.4. Devices for thermochemotherapy
All hyperthermia systems can be used in combinationwith systemic
applied chemotherapy or with more advanced nanoparticles, such as
thermosensitive liposomes as will be discussed in section 6. The differ-
ence between the hyperthermia systems is in their ability to provide
preferential heating of the target volume, i.e. the bulk tumor with a
safety margin around it, and the heterogeneity in the temperature dis-
tribution. Typically, HIFU provides the most targeted heating volume,
but at the same time still has clinically relevant limitations in tumor
size and location. Of the EMbased systems only the radiative hyperther-
mia systems possess the ability to adapt the heating volume to the
tumor and minimize normal tissue heating. Given the ability to heatal., Hyperthermia and smart drug delivery systems for solid tumor
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combinewith nanoparticle smart drug delivery systemswithout limita-
tions for tumor size and location. The latter does not apply for radiofre-
quency capacitive systems as these systems lack the ability to direct the
EM energy to the tumor volume. Hence, for radiofrequency (RF)-capac-
itive systems, preferential tumor heating is only possible when the
tumor has a lower blood perfusion than the surrounding normal tissue.
The latter requirement of a low perfusion is however conﬂicting with
the ability of the nanoparticles to reach the tumor center. For the com-
bination of smart drug delivery systems with MNPs high expectations
exists with respect to its features for tumor speciﬁc heating, increased
drug delivery via magnetic targeting and of triggered drug release via
encapsulation of MNPs in TSLs [175].6. Smart drug delivery systems (SDDS) in hyperthermia
6.1. Introduction to smart drug delivery systems
Smart Drug Delivery Systems (SDDS) can be deﬁned as structures
which incorporate chemotherapeutics, or agents which have an activity
that beneﬁts tumor therapy, and combine that with an additional func-
tionality in order to improve treatment outcome. An example would be
a nanoparticle containing a chemotherapeutic agent that by a tumor
speciﬁc trigger, or responds to an external trigger applied in the tumor
region, releases content. Tumor speciﬁc, internal triggers include a
lower pH [176,177], increased redox [178] or enzymatic activities
[179]. External triggers to which SDDS respond include temperature,
light, ultrasound, electromagnetic ﬁelds, and x-rays [180–185].
The properties of the encapsulated drug, such as pharmacokinetics
and biodistribution, are determined by the carrier. After exposure to
the trigger, for instance mild hyperthermia (~40–43 °C) [186], the en-
capsulated drug is released. The intratumoral concentration of free
drug is therefore determined by the locally inherently present or locally
externally applied trigger.
Improvement of site speciﬁc accumulation with subsequent cellular
or subcellular delivery of the drug into tumor cells with a spatiotempo-
ral control of drug release has long been an unsolved problem for the
scientiﬁc community [187–189]. Using unique pathophysiological fea-
tures of tumor environment combined with the knowledge of design
and fabrication of nanoparticles enabled scientists to equip nanoparti-
cles with a variety of different kinds of functionalities to improve cellu-
lar drug delivery. To date, a variety of stimuli responsive nanoparticles
with one ormulti-stimuli responsiveness have been designed and fabri-
cated [190,191].Fig. 5.Depiction of intratumoral drug deliverywhen using different treatment strategies. Only l
tumor because of the small size (sub nm range). When encapsulated in long circulating nanop
space. However, tumor characteristics discussed in the section 3 impair extravasation. Wh
become larger and NPs are able to extravasate. Drug release occurs after that passively. Alter
after administration the tumor region is heated causing instant release of content while NPs ar
up by tumor cells. Secondly, preheating is combined with heating during administration. The
a second heat does is given to trigger release of drug.
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therapy, Adv. Drug Deliv. Rev., https://doi.org/10.1016/j.addr.2020.02.004Endogenous trigger-sensitive nanoparticles mainly suffer from a
lack of deﬁned and site speciﬁc response due to diminutive and hetero-
geneous differences between normal and malignant tissue as tumor-
characteristics tend to be broad and overlap with conditions in healthy
tissue. Besides, the kinetics of enzyme activity or redox reactions are rel-
atively slow, limiting responsiveness. Importantly, the delivery of these
particles mainly relies on the EPR effect and the stimulus is passive, i.e.
active spatiotemporal control is not possible (Fig. 5). Exogenous stimuli
such as light [192,193], ultrasound [194–196], electromagnetic waves
[180,185] and heat on the other hand not only provide an active spatio-
temporal control of drug release, but it has been demonstrated that
some external stimuli such as sonoporation [197,198] or hyperthermia
[32,66,199] improve tumor permeability for nanoparticles. Thus, a
more precise and controlled release of content from trigger-
responsive nanoparticles can be achieved through the use of a non-
invasive triggers such as mild hyperthermia as discussed in section 5
(Figs. 1, 6).
Here, wewill focus on heat-responsive nanoparticles as this type has
been studied most widely and progressed the furthest towards clinical
translation. Suchnanoparticleswith heat-triggered release functionality
can be broadly divided into twomain groups: liposomal based andpoly-
meric based nanoparticles. For both types, the driving force for drug re-
lease is a physical phase transition in response to temperature.
Thermal responsiveness of thermosensitive liposomes (TSLs)mainly
relies on permeabilization of the lipid bilayer at grain boundary defects
formed between solid phase domains and liquid phase domains during
phase transition of DPPC [200,201]. While liposomes composed of pure
1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC, membrane tran-
sition temperature (Tm) 41.5 °C) have a slow release rate over a wide
temperature range, by addition of other phospholipids (e.g. 1,2-
distearoyl-sn-glycero-3-phosphocholine (DSPC), Tm 54 °C),
alkylphosphocholines (e.g. hexadecylphosphocholine (HePC)) [202] or
lysophospholipids (e.g. 1-palmitoyl-sn-glycero-3-phosphocholine, 1-
stearoyl-sn-glycero-3-phosphocholine) [203] onemay adjust both tran-
sition temperature and release rate [204]. DPPC-based TSLs can be
tuned to release content fast (within seconds), and release rate is af-
fected by presence of serum components as well as percentage of
PEG; in our studies, 5 mol% of PEG provided the best results [205].
Pegylation not only provides steric hindrance and the prolonged circu-
lation time discussed earlier, but also stabilizes the leakiness of TSLs at
physiological conditions.
In polymer based nanoparticles, thermal responsiveness results
from a change in solubility of polymers in aqueousmedium in response
to a temperature changes [206]. Two types of polymers, those exhibiting
a lower critical solution temperature (LCST), having lower solubility atimited free drugwill pass the tumor but will have, when unbound, easy access to enter the
articles (NPs) more drug will pass the tumor and more could enter the tumor interstitial
en mild hyperthermia is applied before administration gaps between endothelial cells
natively, drug release can be initiated by locally applied hyperthermia. First, during and
e still in the bloodstream. Free drug diffuses into the tumor interstitial space and is taken
pre-heating promotes extravasation of NPs and when maximum accumulation is reached
al., Hyperthermia and smart drug delivery systems for solid tumor
Fig. 6. Graphic illustration of radiofrequency ablation (RFA) of a liver tumor in combination with doxorubicin-loaded thermosensitive liposomes (DTSLs). The liver tumor is heated
centrally causing a temperature gradient outwards leading to direct cell kill in the grey colored area. The pushing front at the bottom of the tumor, the inﬁltrating tumor parts at the
top, as well as metastases outside of the ablation zone are not directly affected. At the periphery and around the tumor a zone exists in which tumor cells are not killed directly by the
heat but a mild hyperthermia is reached which triggers DTSLs to release content causing cell kill in that region. In the zoom in on the right the ablation zone (grey), mild hyperthermia
zone (beige) and zone in which doxorubicin release is maximum (red) is depicted. As DTSLs have a sharp optimum release-temperature release outside this temperature region, both
above and below, is impaired or absent. This may cause insufﬁcient drug levels in the region between ablation and triggered drug release (stripped area) as well as in the region close
to body temperature. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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temperature (UCST), having higher solubility at increased tempera-
tures, have been employed for fabrication of temperature-sensitive
polymeric nanoparticles, such as micelles, nanogels and nanoparticles.
Poly-N-isopropylacrylamide (PNIPAAm) is of themost studied polymer
in thisﬁeld. At temperatures below the LCST, hydrogen bonding interac-
tions with water keep this polymer in an expanded coil state due to the
dominant effect of the hydrophilic part of PNIPAAm. An increase in tem-
perature weakens the hydrophilic hydrogen bonds making the hydro-
phobic effect predominant, in which polymer-polymer interactions
outbalance polymer-water interactions; as a result, polymers phase-
out from the solution resulting in a collapsed globule state. Upon this
temperature dependent transition in polymer solubility a swollen hy-
drated polymer turns into a shrunken dehydrated polymer accompa-
nied with about 90% volume loss, accompanied by drug release.
However, PNIPAAm alone is not suitable for heat triggered release
nanoparticles. Introduction of more hydrophilic residues by co-
polymerization of PNIPAAmwith hydrophilicmonomers [207,208] suc-
cessfully increased the LCST. Copolymerization with hydrophobic
monomers [208–210] enhances micellar formation, incorporation
yield of hydrophobic chemotherapeutics and stability of nanoparticles
in aqueous media. Importantly, almost all these thermosensitive poly-
meric nanoparticles exhibit a release at temperature below the LSCT
and require long duration of hyperthermia, up to few hours, to release
a signiﬁcant amount of their payload, which is difﬁcult to translate to
the clinical setting and which limits successful testing in preclinical in-
vestigations.While the response rates of purely polymeric nanoparticles
were not encouraging, the introduction of thermosensitive polymers on
the outer surface of liposomes providedmuch faster release rates, how-
ever at a relatively high temperature of 45 °C [211,212], where vascular
destruction/shutdown may impair blood perfusion and thus limit TSL
supply to the target region. Thermosensitive polymer-modiﬁed lipo-
somes have been reviewed by Kono [213] and Al-Ahmady et al. [214].
More sophisticated hybrid nanoparticles in which TSLs or
thermosensitive polymers were combined with a metallic nanoparticle
have also attracted considerable attention. Such systems do not rely on
direct heat application, but heat is generated by the metallic nanoparti-
cle in response to other external stimuli such as electromagnetic ﬁelds
(EMF) or light. While the use of light has limitations related to a limited
penetration depth in tissue, EMF provide more precise spatiotemporal
control on drug release and offer magnetic guided targeting and
theranostic applications. Iron oxide nanoparticles can be encapsulated
inside [215] or incorporated in the bilayer [216] of DPPC-based lipo-
somes for EMF-induced triggered release. Gold nanoparticles have also
been associated with DPPC-based liposomes for release triggered by
ultra violet [217,218] or near infrared light [219,220]. However, inPlease cite this article as: A.L.B. Seynhaeve, M. Amin, D. Haemmerich, et
therapy, Adv. Drug Deliv. Rev., https://doi.org/10.1016/j.addr.2020.02.004addition to the complexity in formulation of stable preparations of
those types, the release rate of these hybrid systems is relatively slow
(i.e. a few minutes for a signiﬁcant release) and still needs to be
improved.
6.2. Intravascular triggered release from SDDS
The intravascular triggered release paradigm is based on drug re-
lease from the nanoparticle within the vasculature, i.e. while blood
and nanoparticle transit through the tumor. It has been established
that for this intravascular triggered release paradigm, triggered nano-
particles with rapid release (i.e. within seconds) are required [221].
Yatvin et al. published the ﬁrst design of a lipid-based nanoparticle
which responds to mild hyperthermia by triggered release of the con-
tents [222]. This TSL consisted of DPPC:DSPC (3:1 byweight) withmax-
imum release over ~30 min, at a temperature range of 42.5–44.5 °C.
Over the recent decades this prototypical formulation has considerably
evolved in order to improve its therapeutic potential, with the goal of
improving stability and enhancing the release rate. By increasing the
DPPC to DSPC ratio, a faster and sharper release at lower temperatures
was achieved [223–226]. However, release kinetics were still relatively
slow, circulation time in animal models short and aggregation occurred
[137]. Incorporation of GM1 increases circulation time of liposomes
[65]. However, the release rate was not sufﬁcient as only 45% of encap-
sulated doxorubicin was released after 5 min incubation at 42 °C. To re-
duce the premature release, Gaber et al. incorporated 16% cholesterol
(half of what is required to abolish phase transition) and show that
60% of content was released within 30 min [227]. We and others incor-
porated PEGylated phospholipids [205,227], which not only prevented
aggregation and prolonged circulation time, but also accelerated trig-
gered drug release at the membrane transition temperature (Tm). It
has been postulated that PEG stabilizes membrane deformation and
grain boundaries and therefore facilitates rapid transfer of the amphi-
philic drug doxorubicin [228].
For nanoparticles based on the intravascular triggered release para-
digm to be most effective, TSLs have to fulﬁl two basic requirements.
First, after injection and during subsequent circulation the formulation
should be as stable as possible withminimal clearance, minimal release
of content andminimal accumulation in off-target sites. Second, TSLs in
this setting need to release content fast and efﬁcient, ideally within sec-
onds as is discussed elsewhere in this issue. In addition, theproperties of
the encapsulated drug affect delivery efﬁcacy. Ideally, the released drug
easily penetrates the tumor, crosses the vascular wall rapidly, and has a
fast diffusion in the tumor interstitial space, with rapid cellular uptake.
As shown in Fig. 5, TSLs enter a preheated region and while traversing
through this region release content within the bloodstream. Clearly,al., Hyperthermia and smart drug delivery systems for solid tumor
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Moreover, as all drug is released in the blood, transport away from the
tumor by blood ﬂow is likely, hence the need for fast extravasation
and diffusion of the released drug. We demonstrated using intravital
microscopy that optimized DPPC-DSPC pegylated TSLs release instantly
massive amounts of drug at 42 °C, either carboxyﬂuorescein (a model
drug), or the agent doxorubicin, resulting in over 30-fold delivery en-
hancement of doxorubicin compared to doxorubicin administered as a
free drug [122,205]. Manzoor et al. observed by intravital microscopy
that intravascular triggered release from TSLs resulted in deep penetra-
tion and homogeneous intratumor distribution of doxorubicin, while
administration of free doxorubicin, and hyperthermia, only resulted in
low levels in some parts of the tumor [33]. Additionally, when
doxorubicin-loaded TSLs were combined with local hyperthermia, we
observed by intravitalmicroscopymassive uptake of doxorubicin by en-
dothelial cells [122]. Resulting vascular damage could very well explain
part of the improved tumor response we and others have reported
[122,229,230]. An important step forward in the application of TSLs
for solid tumor treatment is the introduction of lysophospholipids into
liposomes, which based on their characteristics render fast (within sec-
onds), release of doxorubicin. Needham et al. incorporated lysolipids in
so-called low temperature sensitive liposomes (LTSLs) [231] resulting
in the thus far most successful TSL formulation that is currently being
commercialized under the name Thermodox® [228]. First clinical trials
have been conducted using Thermodox® (doxorubicin loaded TSLs) in
combination with radiofrequency ablation (RFA) for liver cancer (Clini-
cal trial number NCT02181075) [232], as well as together with micro-
wave hyperthermia for recurrent chest wall cancer [233]. With RFA
the tumor is heated to a temperatures above 50 °C, directly killing
tumor cells by heat [234]. For liver-conﬁned liver cancer (Fig. 6) such
as hepatocellular carcinoma (HCC) RFA might provide a possibility to
control local disease [235,236]. However, as the tumor spreads in sur-
rounding tissue effective ablation of all tumor tissue may not be
reached. To this end TSLs are co-administered as around the ablative
zone a region with mild hyperthermia is established in which TSLs are
triggered to release content [237–239]. The ﬁrst Phase III trial of this
combination therapy (HEAT trial; clinical trial number NCT00617981)
shows no therapeutic beneﬁt of this combination in HCC patients,
with the exception of a subgroup of patients with solitary tumors and
a RFA dwell time of more than 45 min [240]. Further analysis of this
trial identiﬁed several issues which may have contributed to the trial
failure [241]. More so, the intrinsic instability of LTSLs together with
the late start of heating may have been crucial. Plasma clearance of
doxorubicin in patients receiving 50 mg/m2 Thermodox® shows a
rapid buildup of free doxorubicin of about a third of the total doxorubi-
cin administered, reachingmaximum at 30min,which is also the end of
infusion of Thermodox® [228]. Thus Thermodox® instantly releases a
signiﬁcant portion of the encapsulated doxorubicin when in contact
with blood, which will be cleared fast and is not likely to reach the
tumor. Together these factors, treatment setup and plasma clearance,
indicate that a signiﬁcant fraction of LTSLs passing the tumor had al-
ready released doxorubicin before getting to the heated area, i.e. the
tumor, certainly if the tumor is heated after Thermodox® is injected.
Secondly, elaborating on the sufﬁciently heated area concept, in our vi-
sion combining RFAwith a lipid-based nanoparticle is not a happymar-
riage. Liver cancer, for instance HCC andmetastasis of colorectal cancer,
have a inﬁltrative or expansive growth pattern [242], and may be mul-
tifocal [243]. As boundariesmay not be clear, tumormay extend into the
liver or metastasis may be present and as a result not all tumor tissue is
ablated. To solve this LTSLs are added which release content in the sub
50 °C heated area; or at least that is the hypothesis. In Fig. 6 we show
RFA of HCC, showing both inﬁltrative growth and metastasis. The ab-
lated region is indicated as well as the temperature zones around this
region in which temperature drops until it reaches body temperature.
It is crucial to realize that lipid-based thermosensitive SDDS have an op-
timal temperature, the membrane transition temperature (Tm), atPlease cite this article as: A.L.B. Seynhaeve, M. Amin, D. Haemmerich, et
therapy, Adv. Drug Deliv. Rev., https://doi.org/10.1016/j.addr.2020.02.004which release is maximum [203,204,226]. Below, but also above the
Tm release drops rapidly, both in rate and in maximum amount. This
means that only in a deﬁned and limited area doxorubicin is efﬁciently
released resulting in regrowth of the cancer from those parts. Finally, as
we discuss below, doxorubicin might not be the best drug choice for
liver cancer [199].
Nevertheless, based on the response of a sub-group of patients in the
RFA + Thermodox® trial (HEAT trial) where RFA duration was above
45 min, pre-clinical follow-up studies were performed. These studies
demonstrated that drug delivery is enhanced at longer heating dura-
tions [237,239]. Results are expected from a follow-up phase III trial
(OPTIMA) combining RFA with Thermodox® which completed enroll-
ment in August 2018 (clinical trial number NCT02112656) [244]. The
Data Monitoring Committee recommended recently to continue the
trial as progression free survival was better than observed in the HEAT
trial while other data is consistent which what was observed in the
HEAT trial subgroup [245]. This suggests that a longer RFA dwell time
of 45 min or more may render better results and may reduce local
recurrence.
Recently the TARDOX phase I trial using HIFU-induced mild hyper-
thermia demonstrated that local HT results in a 3.7-fold increased
intratumoral drug concentration comparing drug levels before HIFU in-
duced drug release and after HIFU [155,246].While these results are not
as promising as prior pre-clinical studies, this was the ﬁrst study dem-
onstrating in human tumors that tumor drug uptake can be enhanced
with thermosensitive liposomes. For example, prior studies in a rabbit
liver tumor model with HIFU hyperthermia and Thermodox® showed
a 26.7-fold increase in tumor drug uptake [247]. One limitation of the
TARDOX trial likely contributing to the lower tumor uptake than in pre-
clinical studies was, that tumor temperature in this trial was not accu-
rately controlled or monitored [241,248]. Another contributing factor
was the delay after injection of Thermodox® before heatingwas started
[155]. And this is a crucial aspect in intravascular triggered drug release.
As stipulated above and depicted in Fig. 2, TSLs are in general unstable in
circulation, irrespective of size, pegylation or other long circulating
properties. For instance, as mentioned above, Thermodox® leaks part
of the contents during infusion [249,250], which can however be re-
duced by adding up to 10% cholesterol without affecting release rate
[251]. In addition, TSLs tend to have signiﬁcantly shorter plasma half-
lives (typically around 1 h) compared to a liposomal stealth formulation
like Doxil® (i.e. days) [46,142]. Thus, pre-heating of the tumor prior to
injection may be beneﬁcial; in the two mentioned trials, hyperthermia
was applied for 12 min to 1 h when combined with RFA (HEAT trial),
and around 40 min when used with HIFU hyperthermia (Tardox trial)
[155,252]. A direct correlation exists between the duration of hyper-
thermia, and the locally delivered drug concentration [253], although
the used temperatures of 45 and 50 °C are relatively high and vascular
damage is likely in close proximity of the heating probe. The instability
of TSLs and the need for optimal temperature at the target zone (i.e.
tumor) preferably at the Tm and such that tumor vessels are not dam-
aged introduces another important factor. When TSLs pass through re-
gions with inadequately low temperature, triggered release is slow
and partial. Uneven heating, unheated tumor zones, and zones with
toomuch cooling are exampleswhichnegatively affect triggered release
and therefore outcome [241]. This is in addition to heterogeneous distri-
bution of the TSLs because of above discussed tumor vasculature related
inadequacies. If one would argue, and unfortunately this does happen,
that therefore it would be better to set the local target temperature
higher, this is for several reasons ill-advised. First, overheating a region
is often accompanied by a higher chance of unwanted side-effects such
as burns, heating duration limiting pains and damage to healthy tissues.
Second, when local temperatures are above 42 °C, endothelial damage
in tumors occurs, resulting in destruction of vessels, stasis and thus
poor perfusion of that region, resulting in poor drug delivery. Thirdly,
as mentioned above, TSLs show impaired triggered drug release when
temperatures are applied above the Tm, and show fastest release atal., Hyperthermia and smart drug delivery systems for solid tumor
13A.L.B. Seynhaeve et al. / Advanced Drug Delivery Reviews xxx (2020) xxxthe Tm as explained by Papahadjopoulos et al. [204] and Lu et al. [226].
More recently the group of Lindner et al. developed a new non-
PEGylated TSL in which 1.2-dipalmitoyl-sn-glycero-3-
phosphoglyceroglycerol (DPPGOG or DPPG2) was used to enhance the
circulation time of liposomes, with promise of no reduction by acceler-
ated blood clearance upon repeated injection as is shown to result from
the use of PEGylated products [254]. Like PEG, DPPGOG also facilitates
temperature-triggered drug release and shows comparable release
rates as that observed in lysolipid-based TSLswith however a higher de-
gree of stability at 37 °C [255]. Since the optimum size for long circula-
tion is between 70 and 200 nm they used 200 nm liposome size to
take the advantage of higher drug/lipid ratiowhere doubling the size in-
creases available loading volume by eightfold that leads to more efﬁ-
cient intravascular drug release. These allow the DPPG2 TSL to
circulate long and therefore the possibility to pass the hyperthermic
area after injection more often. Doxorubicin-containing DPPG2-TSL
combined with local hyperthermia indicated promising therapeutic ef-
fects in treatment of feline soft tissue sarcoma in advanced stage of dis-
ease [256]. Interestingly themaximal tolerated dose was not reached in
this trial indicating that possibly higher doses can be used with the
chance of higher response rates. We previously published a better re-
sponse when using optimized DPPC based TSLs with doxorubicin com-
pared to LTSLs [122]. This may result from the reduced stability of LTSLs
mentioned above resulting in a signiﬁcant level of free doxorubicin in
circulation while no hyperthermia is applied. Moreover, that could
also explain why in this study mice treated with LTSLs without heat
show a better tumor response compared to DPPC-based TSLs. The
group of Dewhirst compared different TSLs: classic cholesterol contain-
ing TSL responding optimally to 42°-45 °C, LTSLs responding to a lower
temperature of 39–40 °C and non-temperature sensitive liposomes
[257]. They found LTSLs to be superior in drug delivery and tumor re-
sponse, which may be explained by the slow release from the classic
TSLs, which contained 16% cholesterol as well as a relatively low per-
centage of DPPC (54%) [257]. To ensure fast release from DPPC-based
TSLs a DPPC content of 70–80 mol% is optimal, and cholesterol should
not be included [258].
Interestingly, intravascular release may introduce an aspect not en-
countered when drugs are injected in the free form: a local concentra-
tion too high to be accumulated in time by tumor cells. Intravascular
triggered release as explained above results in a rapid buildup of free
drug in a relatively small volume. We and others observed a decline in
drug levels after heating was stopped and drug not yet taken up by
cells diffused back to tumor vessel [122]. One way to deal with that is
using drugs which are rapidly taken up by cells (Fig. 7). We published
recently fast and efﬁcient uptake by tumor cells of idarubicin, a moreFig. 7. Depiction of the effect of drug uptake and retention in tumor cells on intratumoral
drug kinetics. In the left panel a drug is represented with fast diffusion but slow cellular
uptake and poor intracellular retention. The net result is a relatively low concentration
in tumor cells and a high exposure to healthy tissues. The right panel represents a drug
with comparable diffusion but fast cellular uptake and high intracellular retention. Here
the concentration in cell will be higher and more likely capable of killing while systemic
levels remain lower.
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local drug accumulation and tumor response results (Fig. 2) [199].
These observations are in agreement with a different local drug de-
livery method, hepatic artery infusion (HAI) which has been employed
for treatment of liver cancers. For HAI, it is clinically accepted that opti-
mal results are achievedwith agents that are rapidly extracted by tissue
[15,259]. For example, the agent 5-ﬂuorouracil (5-FU) with moderate
extraction fraction (30–40% of drug are extracted during a single pass
through the liver) increases tumor drug exposure only 5–10 fold
when administered by HAI compared to systemic delivery, and admin-
istration via HAI does not provide a therapeutic beneﬁt. However, 5-
ﬂuoro-2′-deoxyuridine, a drug analog of 5-FU, enhances tumor drug ex-
posure ~100–400 fold due to rapid extraction (94–99% are extracted
during a single pass through the liver), and does provide therapeutic
beneﬁt over systemic administration. These results are directly applica-
ble to localized delivery by intravascular triggered SDDS, since the re-
lease of bioavailable drug within the tumor vasculature can be
considered as direct infusion of bioavailable drug into the tumor (i.e.
similar to HAI).
Alternatively, the cellular uptake of chemotherapeutics can be im-
proved. We and others observed a faster intracellular accumulation of
doxorubicinwhen these cellswere exposed to short chain sphingolipids
such as glucosylceramide [260,261]. Others used ultrasound to
permeabilize cell membranes to facilitate intracellular accumulation of
a cell impermeable test drug released from TSLs [262]. Together these
examples show that aiding or improving drug accumulation may be
an essential part of intravascular triggered drug delivery to be optimally
effective.
Importantly, computational modeling of intravascular release using
optimally tuned TSLs indicates that intravascular triggered release
method is superior in delivery of doxorubicin when compared to
other methods including the two step approach [221,263]. The group
of Papahadjopoulos reported that heating of a tumor to 42–45 °C in-
creased both liposome content (47-times versus unheated) and doxo-
rubicin content (38–76-fold versus unheated) in the tumor [66].
6.3. Extravascular triggered release from SDDS
A major aspect which drove the development of nanoparticles for
drug delivery in cancer is the tendency of particles to accumulate in tu-
mors. A direct correlation between tumor accumulation and circulation
time has been demonstrated; the longer a particle circulates the more
ends up in a tumor. This EPR effect can be considered as the holy grail
in nanoparticle-mediated drug delivery, however as stated above is
under debate.We and others observed that the EPR effect plays actually
only a minor role, seems to occur mainly in fast growing tumors and if
present is rather heterogeneous [32,69]. In humans, particularly the
leakiness of vessels, and thus the EPR effect, is much less pronounced
as compared to the often fast growing mouse tumors. Irrespective of
that, the tumor associated vasculature presents an immature makeup,
does have gaps between endothelial cells and preferential accumulation
is seen [61,73]. Importantly, the endothelial lining of tumor vessels re-
sponds to internal and external triggers different frommature and qui-
escent endothelial cells in normal vessels. As outlined above the degree
of leakiness, and thus EPR effect, is augmented by certain cytokines,
vaso-active agents, but also hyperthermia [32,69]. Combination of hy-
perthermia and long circulating nanoparticles (Fig. 1) therefore results
in higher intratumoral delivery and improved outcome in animal stud-
ies [66,122,199,264]. We and others proposed to combine
hyperthermia-mediated extravasation with hyperthermia-mediated
triggered drug release and coined this a two-step approach as demon-
strated by Li et al. (Fig. 5) [263,265]. In this setting the tumor is ﬁrst
heated mildly to about 42 °C and allowed to regain body temperature.
This results in changes in the tumor vasculature allowing higher accu-
mulation of subsequently injected nanoparticles. When maximum ac-
cumulation has been achieved, which is for long circulatingal., Hyperthermia and smart drug delivery systems for solid tumor
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hyperthermia is applied triggering release of contents from the
intratumoral particles. Li et al. show that this treatment setting is how-
ever less effective with respect to tumor response as compared to the
above discussed intravascular triggered release approach, while local
drug levels reached in the two methods were the same [263]. It is im-
portant to note that the nanoparticles used in the two settings are differ-
ent. So-called slow release thermosensitive liposomes (sTSLs) where
used in the two-step method. These sTSLs only release their content
overminutes at 42 °Cwhile a signiﬁcant fraction of the sTSLs retain con-
tents even after 1 h of heating. Possibly another TSLs, better equipped
for the two-stepmethod rendered better results. Together these results
indicate that possibly intact doxorubicin-containing TSLs are present in
the interstitial space when the two-step method is combined with slow
release TSLs. Therefore, this slow release method is likely not the best
choice to deliver a chemotherapeutic compound like doxorubicin, but
may be an interesting option for other drugs. Similarly, Cha et al. used
HIFU to initially increase vascular permeability followed by injection
of TSLs containing doxorubicin [266]. After 6 h, when maximum
tumor accumulation was achieved, tumors were heated to 42 °C. They
show that this approach achieved a better tumor response compared
to intravascular release.
For a drug to be active, a local drug concentration needs to be
established which is high enough while the drug needs to be present
for adequate time to act. This drug exposure can be expressed by the
AUC of the drug concentration over time. That means that a high but
short exposure will produce the same AUC compared to a low concen-
tration present for a longer time. What is better really depends on the
drug used. Some drugs need to be converted or are taken up by cells
slowly, have poor diffusion proﬁles, or are accompanied by severe
side-effects. The above described one-step intravascular triggered re-
lease approach is intended to deliver, in a short time-frame, massive
amounts of drug in a relatively small volume. It can be argued that for
most chemotherapeutics this method is preferred. However, the two
step method may provide an interesting possibility to deliver in a con-
trolled manner compounds which beneﬁt from intratumoral release.
First, when a drug enters a tumor the ﬁrst layers of cells accumulate
most, with deeper tumoral regions receiving less drug. Nanoparticles,
especially sterically stabilized for instance with PEG, are taken up by
cells slower and could therefore penetrate deeper and hence when
drug is released this also reaches cells further away from the vessel. Sec-
ond, deposition of particleswhich respond in a slowmanner to a tumor-
intrinsic release trigger could establish sustained drug delivery in the
tumor over extended periods of time. Thirdly, if the particle is equipped
with more than one active component, presence deep in the tumor tis-
sue guarantees simultaneous exposure of the tumor cell to these active
components at the same time. Thismay be of value in combination ther-
apies, vaccination or immunologic treatments. Fourth, the blood brain
barrier (BBB) inhibits delivery of drugs or nanoparticles to brain cancer.
Mild hyperthermia transiently opens the BBB and allows drug to pass.
Here the two step-method may be useful to ﬁrst open the BBB and sec-
ondly release drug from interstitially present liposomes. More so, this
can also be achieved in one hyperthermia dose [253].
7. Future of SDDS and hyperthermia: a marriage for life?
While nanotechnology developed rapidly and nanoparticles
underwent several generations of evolution (for liposomes since the
discovery by Bangham in the 60s), successes in the cancer ﬁeld have
been limited. Currently only a few nanoparticles carrying chemothera-
peutics are approved for patient use, and Doxil® - the most successful
formulation –wasmainly approved because of a favorable toxicity pro-
ﬁle rather than better efﬁcacy [48,49,267–273]. Clearly, further im-
provement, but also a different way of thinking is required to realize
the promise of nanoparticles. The nanoparticles currently dominating
nanomedicine are relatively stable and therefore release slowly, orPlease cite this article as: A.L.B. Seynhaeve, M. Amin, D. Haemmerich, et
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thermosensitive hydrogels can bemade which at body temperature re-
lease a steady level of drug over long duration [274,275]. While this
steady and slow release may be useful in some settings, for effective
tumor cell kill high drug levels and thus rapid release aremore effective.
A recent proposed hypothesis is that amore controlled, so-called immu-
nologic cell death may result in a systemic response and possibly cure.
When the tumor is killed in this rather subtle way an immunologic re-
sponse may occur which may kill not-targeted metastases and render
immunity towards the cancer [276–278]. In spite of this, bringing ade-
quate drug amounts to all tumor cells is still a goal.
The question is whether combination of nanodevice-mediated drug
delivery through the use of SDDS in combination with mild hyperther-
mia is a viable approach. This question raises several concerns and is-
sues which need to be addressed. First, a question often encountered
when results with controlled locally triggered drug release is: what to
do about micrometastasis? The rationale is that patients do not gener-
ally die from the primary or locally advanced tumor but from progres-
sion of micrometastases. Do we need additional infusion of free drug
to kill micrometastasis? Can we use a drug which is released from
SDDS to attack these? Or can we improve non-invasive detection and
target smaller, currently undetectable tumors? Or is it feasible to
achieve regional delivery with SDDS in organ or tissue volumes where
micrometastases are suspected? And if so, can we repeat treatment
again and again to achieve local control as soon as micrometastases be-
come detectable? If this is not possible currently or in the near future, is
local control a clinically sufﬁcient goal for continuing SDDS research? As
discussed above, a combination that already underwent a trial, with an
ongoing follow-up trial is TSLs togetherwith ablation.While this combi-
nation may reduce recurrences in the margin of the ablation zone and
thus reduce overall local recurrence rates, there are several concerns
as discussed above.
Another important factor complicating cancer therapy through
hyperthermia-triggered drug release from SDDS is that a hyperthermia
device is required, and that device performance is as important as SDDS
properties. As described above there are several methods to heat re-
gions in the body but all have advantages as well as limitations and
drawbacks. Currently, there is no ideal heating protocol and therefore
the ﬁeld has not developed to its full potential. Providing homogeneous
and tumor speciﬁc heating to the required temperaturewithout damag-
ing surrounding health tissues is still a distant future goal, since expo-
sure of large tissue volumes to a relatively narrow temperature range
(~40–42 °C) is technically very challenging. This together with the al-
ready discussed heterogeneity of solid tumors, which affects SDDS pres-
ence, confronts the ﬁeld with complex issues that still need to be
resolved. Possibly, treatment parameters need to be optimized in a
patient-speciﬁc manner to be effective. This will make clinical studies
difﬁcult to conduct as it will be hard to recruit enough patients. Here,
more recent developments could provide at least part of an answer.
By computational modeling of drug delivery, drug distribution, re-
sponse to heat triggering, impact of perfusion, patient characteristics
and behavior of different TSLs with different drugs, insights into treat-
ment options can be studied and the best selected or even tuned per pa-
tient. More so, if we could validate the different processes modeled and
could improve on themodels devised, this approach couldwell be a cru-
cial element inmaking the SDDS+ hyperthermia combination success-
ful. An important question which needs to be looked at is if doxorubicin
is the best drug for this setting. At the moment this drug is by far the
most widely used in thermosensitive nanodevices for cancer therapy.
As discussed above, we hypothesized recently that the SDDS-
Hyperthermia approach is actually a local therapy, and therefore should
be looked at as such.We argue that drugs need to be selectedwith char-
acteristics which are especially of beneﬁt in such a setting. Another
question, and likely related to the one just asked, is: why is the tumor
response not as good as expected, since we do get more drug in the
tumor when SDDS are used in combination with hyperthermia?al., Hyperthermia and smart drug delivery systems for solid tumor
15A.L.B. Seynhaeve et al. / Advanced Drug Delivery Reviews xxx (2020) xxxThe future of hyperthermia-mediated triggered drug release from
SDDS for the treatment of cancer is therefore obscured by the many as-
pects which determine success. In other words, there are many aspects
which could all, independently or in combination, result in failure. Cur-
rent research is and needs to be focused on how to get the most syner-
gistic interaction between SDDS, hyperthermia, patient and tumor. For
this a solid interaction between the different disciplines is key.
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